DiaMedica Therapeutics Inc. financial data

Symbol
DMAC on Nasdaq
Industry
Pharmaceutical Preparations
Location
301 Carlson Parkway, Suite 210, Minneapolis, MN
State of incorporation
Canada (Federal Level)
Fiscal year end
December 31
Former names
DiaMedica Inc. (to 3/11/2014)
Latest financial report
10-K - Q4 2024 - Mar 17, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.29K % -27.6%
Return On Equity -51.9 % -29.5%
Return On Assets -47.7 % -25.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.9M shares +12.9%
Common Stock, Shares, Outstanding 42.8M shares +12.8%
Entity Public Float 71M USD
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 40.4M shares +24.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 19.1M USD +45.4%
General and Administrative Expense 7.62M USD -6.53%
Operating Income (Loss) -26.7M USD -25.5%
Nonoperating Income (Expense) 1.93M USD +446%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -24.4M USD -26.2%
Income Tax Expense (Benefit) 30K USD -30.2%
Net Income (Loss) Attributable to Parent -24.4M USD -26.1%
Earnings Per Share, Basic -0.6 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.03M USD -33.4%
Marketable Securities, Current 41.1M USD -15%
Cash, Cash Equivalents, and Short-term Investments 44.1M USD -16.6%
Accounts Receivable, after Allowance for Credit Loss, Current 236K USD -36%
Assets, Current 44.6M USD -16.9%
Property, Plant and Equipment, Net 148K USD +13%
Operating Lease, Right-of-Use Asset 279K USD -21.2%
Assets 46.3M USD -14.4%
Accounts Payable, Current 940K USD +1.51%
Employee-related Liabilities, Current 1.06M USD +38.4%
Accrued Liabilities, Current 4.35M USD +145%
Liabilities, Current 5.39M USD +93.5%
Operating Lease, Liability, Noncurrent 225K USD -28.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 23K USD +283%
Retained Earnings (Accumulated Deficit) -140M USD -21.2%
Stockholders' Equity Attributable to Parent 40.7M USD -20.3%
Liabilities and Equity 46.3M USD -14.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.65M USD -30.7%
Net Cash Provided by (Used in) Investing Activities 4.21M USD +67.7%
Common Stock, Shares, Issued 42.8M shares +12.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.45M USD +5.23%
Deferred Tax Assets, Valuation Allowance 34.2M USD +21.9%
Operating Lease, Liability 315K USD -20.5%
Depreciation 8K USD +14.3%
Payments to Acquire Property, Plant, and Equipment 9K USD +28.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -24.4M USD -26.6%
Lessee, Operating Lease, Liability, to be Paid 358K USD -23.3%
Property, Plant and Equipment, Gross 262K USD +13.4%
Operating Lease, Liability, Current 90K USD +12.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 116K USD +2.66%
Lessee, Operating Lease, Liability, to be Paid, Year One 113K USD +3.67%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 43K USD -39.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 119K USD +2.59%
Deferred Tax Assets, Operating Loss Carryforwards 32.2M USD +23.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10K USD -91.6%
Additional Paid in Capital 181M USD +8.46%
Deferred Tax Assets, Net of Valuation Allowance 34.2M USD +21.9%
Share-based Payment Arrangement, Expense 2.09M USD +23.9%